Management of Elevated Parathyroid Hormone with Normal Calcium Levels

Initial Evaluation

For patients with elevated PTH and normal serum calcium, first evaluate for modifiable factors including hypocalcemia, hyperphosphatemia, vitamin D deficiency, and high phosphate intake before initiating treatment, as recommended by the Kidney International guidelines 1
Assess for common causes of secondary hyperparathyroidism with normal calcium, including vitamin D deficiency (25-OH vitamin D <30 ng/mL), according to the American Journal of Kidney Diseases guidelines 2
Evaluate for chronic kidney disease (check eGFR) in patients with elevated PTH and normal calcium, as suggested by the American Journal of Kidney Diseases guidelines 3
Consider medications affecting calcium metabolism as a potential cause of secondary hyperparathyroidism, as noted in the Endocrine Reviews guidelines 4

If vitamin D deficient (25-OH vitamin D <30 ng/mL), supplement with cholecalciferol or ergocalciferol to achieve levels ≥30 ng/mL, as recommended by the Praxis Medical Insights guidelines 2
For patients with hyperphosphatemia, reduce dietary phosphate intake and consider phosphate binders if dietary modification is insufficient, according to the Kidney International and American Journal of Kidney Diseases guidelines [1] [3]

Check serum calcium and phosphorus monthly for the first 3 months, then every 3 months, and measure PTH levels every 3 months for 6 months, then every 3-6 months thereafter, as recommended by the Praxis Medical Insights guidelines 2
If PTH normalizes, continue current management, and if PTH falls below target range for CKD stage, hold vitamin D therapy until PTH rises above target, then resume at half the previous dose, according to the Praxis Medical Insights guidelines 2
If serum calcium exceeds upper limit of normal, hold vitamin D therapy until calcium normalizes, as recommended by the Kidney International guidelines 1

In patients with CKD, do not attempt to normalize PTH to the range for patients without CKD, as this may lead to adynamic bone disease, according to the Praxis Medical Insights guidelines 2
Avoid hypercalcemia and hyperphosphatemia, which can increase the risk of vascular calcification, as noted in the Praxis Medical Insights guidelines 2

Failing to recognize that "intact PTH" assays may detect biologically inactive fragments, potentially overestimating true PTH activity, as discussed in the Endocrine Reviews guidelines 4
Not accounting for factors that influence PTH levels, such as race, BMI, and age, according to the Endocrine Reviews guidelines 4
Attempting to normalize PTH levels in CKD patients, which may lead to adynamic bone disease, as warned by the Praxis Medical Insights guidelines 2